Ziconotide vs B7-33
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Prialt, SNX-111
Ziconotide is a real, FDA-approved painkiller pulled from the venom of a marine cone snail. It is not an opioid, and unlike morphine, people do not build tolerance to it over time. The catch: it only works delivered directly into the spinal fluid through an implanted pump, and its side effect profile is rough enough that it carries a black box warning.
Also: B7-33 relaxin, Single-chain relaxin-2 analog
B7-33 is a 27-amino-acid, single-chain peptide cut down from the B-chain of human relaxin-2, the hormone that loosens tissue during pregnancy. Relaxin itself has strong anti-scarring effects but is a complex two-chain molecule that is hard and expensive to make, so an Australian group (Hossain and colleagues, 2016) designed B7-33 as a simpler version. In rodent models it reduced heart and lung fibrosis about as well as full relaxin. It has never been tested in humans.
Key Comparison Insights
- Ziconotide is FDA approved, while B7-33 remains in research stages.
- Both peptides belong to the Healing category, suggesting similar primary applications.
- Ziconotide has stronger research evidence (FDA Approved) compared to B7-33 (Preclinical).
Detailed Comparison
| Attribute | Ziconotide | B7-33 |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Ziconotide is a synthetic copy of omega-conotoxin MVIIA (originally SNX-111), a 25-amino-acid peptide with three disulfide bonds found in the venom of the cone snail Conus magus. It blocks N-type voltage-gated calcium channels, which sit on pain-sensing nerves in the spinal cord's dorsal horn. By shutting those channels, it stops the release of pain-signaling neurotransmitters before the message can travel up to the brain. It barely crosses the blood-brain barrier, which is exactly why it has to be infused intrathecally, straight into the cerebrospinal fluid, to reach its targets. | B7-33 activates RXFP1, the relaxin receptor, but in an unusual way. In cells that naturally carry RXFP1 (like fibroblasts), it preferentially switches on the pERK1/2 pathway rather than the cAMP pathway, which made it the first described functionally selective (biased) RXFP1 agonist. Its anti-fibrotic action runs through RXFP1 paired with the angiotensin II type 2 receptor, increasing MMP-2, an enzyme that breaks down collagen. In other words, it pushes scar tissue to be broken down rather than built up. Two practical caveats: it binds RXFP1 poorly in standard engineered cell lines, so its potency depends heavily on the cell type, and it is short-lived in serum (roughly 6 minutes in lab tests), which is why researchers have tried fatty-acid versions to stretch its half-life. |
| Common Dosing | Limited community data available See research protocols | No established human dose Once to twice daily in mouse studies |
| Administration | Intrathecal infusion only | Intraperitoneal or subcutaneous injection (including osmotic minipumps) in rodents |
| Typical Duration | Chronic use via intrathecal pump | 1-2 weeks in most rodent studies |
| Best Time to Take | Morning or as directed | No evidence-based timing |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This one is the opposite of speculative. The FDA approved ziconotide as Prialt on December 28, 2004, and the European Commission followed on February 22, 2005. It is indicated for severe chronic pain in patients who need intrathecal therapy and who cannot tolerate or no longer respond to other options, including intrathecal morphine. Its big advantage over opioids is the apparent absence of tolerance or physical dependence even with long-term use. The big problem is a narrow therapeutic window: dizziness, confusion, memory problems, unsteady gait, and serious psychiatric effects including hallucinations and suicidal thoughts, which is why it carries a black box warning and is contraindicated in people with a history of psychosis. Rapid dosing or aggressive dose escalation makes the adverse effects worse, so it is titrated slowly under specialist care. | The founding paper (Hossain et al., Chemical Science, 2016) reported that B7-33 prevented or reversed organ fibrosis and dysfunction in three rodent models of heart or lung disease with potency similar to full relaxin-2, and, unlike native relaxin, it did not promote prostate tumor growth in mice. That last point matters because relaxin has been linked to tumor growth. Later mouse work extended the findings: Devarakonda et al. (Journal of the American Heart Association, 2020) gave 0.25 mg/kg twice daily by injection after a heart attack and found smaller infarcts, better heart function, and less fibrosis at 7 days. A 2023 follow-up from the original group confirmed that B7-33 cannot be shortened further without losing receptor binding. Important context: the full hormone (serelaxin) went all the way to a large phase 3 trial in acute heart failure (RELAX-AHF-2) and failed both primary endpoints, a reminder that strong animal anti-fibrotic data in this family have not translated easily to people. For B7-33 itself there are no human studies, no human pharmacokinetics, and no human safety data. |
Frequently Asked Questions: Ziconotide vs B7-33
What is the difference between Ziconotide and B7-33?
Ziconotide is a healing peptide that ziconotide is a real, fda-approved painkiller pulled from the venom of a marine cone snail. it is not an opioid, and unlike morphine, people do not build tolerance to it over time. the catch: it only works delivered directly into the spinal fluid through an implanted pump, and its side effect profile is rough enough that it carries a black box warning. B7-33 is a healing peptide that b7-33 is a 27-amino-acid, single-chain peptide cut down from the b-chain of human relaxin-2, the hormone that loosens tissue during pregnancy. relaxin itself has strong anti-scarring effects but is a complex two-chain molecule that is hard and expensive to make, so an australian group (hossain and colleagues, 2016) designed b7-33 as a simpler version. in rodent models it reduced heart and lung fibrosis about as well as full relaxin. it has never been tested in humans. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Ziconotide or B7-33?
Neither is universally "better" - the choice depends on your specific goals. Ziconotide is typically used for healing purposes, while B7-33 is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Ziconotide and B7-33 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Ziconotide and B7-33 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.